Boron Neutron Capture Therapy and Nanotechnology
Toward the Revolutionized Cancer Therapy

研究概要

Radio

Boron Neutron Capture Therapy

Boron Neutron Capture Therapy (BNCT) is a radiation therapy that uses the nuclear reaction between thermal neutrons and boron (Boron-10), to kill cancer cells with the alpha particles and lithium nuclei produced.
When a drug containing boron is administered to the body and irradiated with neutrons, cancer cells are destroyed by the energy released from the boron. The area of effect is localized, and cancer cells can be destroyed while minimizing damage to normal cells. Conventional radiotherapy requires multiple irradiations, but BNCT is expected to be highly effective even with a single irradiation.

Learn more about BNCT

Nano

Nanotechnology

To further enhance the therapeutic effect of this BNCT, we have developed a new product called RN-501, a highly hydrophilic boron-containing inorganic nanoparticles.
The product is designed to deliver to cancer cells in a concentrated manner, which not only reduces side effects, but also makes it applicable to carcinomas that have been difficult to treat. In addition, the product's high accumulation and retention properties enable treatment at lower doses and for shorter periods of time than conventional formulations.

Learn more about nanotechnology

Nanotechnology to enhance the advantages of BNCT
A Next-Generation Radiotherapy
that could be the First Choice for Cancer Treatment.

Our Mission

Contribute to the health and future of cancer patients and their families through the development of novel biologically targeted radiation therapy

RadioNano Therapeutics Inc., a venture company, was established for the social implementation of Boron Neutron Capture Therapy (BNCT) using highly hydrophilic boron-containing inorganic nanoparticles developed by Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies, Kyoto University and Professor Minoru Suzuki of the Institute for Composite Nuclear Science, Kyoto University.

NEWS

We received the "O-Nexus Award" at U-START UP KANSAI 2026, and the "Challenging Spirit Category Audience Award and Special Award" at the EY Entrepreneur of the Year 2026 Japan Kansai Region.

RadioNano Therapeutics Inc. (Headquarters: Kyoto City, Kyoto Prefecture; Representative Director: Masatoshi Chiba; hereinafter referred to as "the Company") has received the "O-Nexus Award" at the open pitch of "U-START UP KANSAI 2026," a program supporting the business development of university-based startups. This program is organized by the Osaka Chamber of Commerce and Industry and the Kansai Innovation Initiative (KSII). Furthermore, we are pleased to announce that our P

Oct 22

First Close of Series B Funding Round Successfully Completed – Advancing to Phase I Clinical Trial of the BNCT Boron Drug Candidate RN-501 –

RadioNano Therapeutics Inc. (Head Office: Kyoto, Japan; President & CEO: Dr.Masatoshi Chiba; hereinafter, the “Company”), a biotechnology company engaged in the research and development of inorganic nanoparticle formulations for Boron Neutron Capture Therapy (BNCT), today announced the successful completion of the first close of its Series B financing round through a third-party allotment of new shares to Mitsui Kinzoku Co., Ltd. and Kyoto University Innovation Capital Co., L

Oct 9

Kyoto Sangyo 21's "Sangaku-ko no Mori" (Industry-Academia-Government Forest) Promotion Program<Full-Scale Business Development Course>

RadioNano Therapeutics Co., Ltd. (President and CEO: Masatoshi Chiba; hereinafter "the Company") is pleased to announce that its research theme, conducted in collaboration with Kyoto University and the Institute for Integrated Radiation and Nuclear Science, Kyoto University, has been selected for the "Ⅲ Full-Scale Business Development Course" under the Fiscal Year 2026 "Sangaku-ko no Mori" (Industry-Academia-Government Forest) Promotion Program, implemented by the Kyoto Small

Sep 28

As a supplementary prize for receiving the Grand Prize from Ikeda Senshu Bank, we participated in a recording of MBS Radio’s program “Nippon Ichi Akarui Keizai Denpa Shimbun.”

We are pleased to announce that we have received the Grand Prize in an award program hosted by Ikeda Senshu Bank. As a supplementary prize, our Representative Director, Mr. Chiba, participated in a recording of the MBS Radio program “Nippon Ichi Akarui Keizai Denpa Shimbun” (Editor-in-Chief: Nobuo Takehara; Announcer: Hiroko Matsukawa). During the recording, we had the opportunity to discuss the initiatives that led to the award, our commitment to our business, and our future

Apr 17

2 3 4 5